I am not such a fan of going it alone. P3 is not much more than a re-hash of P2b, just with better dose control. P3 has been de-risked.
A deal now with the appropriate milestone payments can't be that much less valuable than P3/approved stage - certainly from a royalties perspective. If they can't do a deal now I would have concerns about why not, and going alone on P3 might not return much more consider the dilution impacts.
I'm bailing if they go it alone.
Add to My Watchlist
What is My Watchlist?
